Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice

Toxicology and Applied Pharmacology

Volumn 228, Issue 3, 2008, Pages 315-325

  Barrick, Cordelia J ^a,b   Yu, Ming ^a,b   Chao, Hann Hsiang ^b   Threadgill, David W ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Animal model; Cardiotoxicity; EGFR; Growth factors

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PELITINIB; PROTEIN BCL 2;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOPATHOLOGY; LONG TERM EXPOSURE; MALE; MOLECULAR THERAPY; MOUSE; NEWBORN; NICK END LABELING; NONHUMAN; PHARMACOLOGICAL BLOCKING; UPREGULATION; WEIGHT GAIN;

ANIMALS; AORTIC VALVE; APOPTOSIS; FEMALE; HEART; HEART VENTRICLES; MALE; MICE; MICE, INBRED C57BL; ORGANIC CHEMICALS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX CHARACTERISTICS; TYRPHOSTINS;

ANIMALIA; MUS;

EID: 41949126935     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.12.012     Document Type: Article

References (72)

1. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19 (2001) 32S-40S
2. Baselga J. Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. J. Clin. Oncol. 24 (2006) 2225-2226
3. Brenner H., and Arndt V. Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient. Cancer Causes Control 15 (2004) 903-910
4. Burton A.W., Fanciullo G.J., Beasley R.D., and Fisch M.J. Chronic pain in the cancer survivor: a new frontier. Pain Med. 8 (2007) 189-198
5. Carlson F.L. Histotechnology: a self-instructional text (1990), ASCP Press, Chicago
6. Cersosimo R.J. Gefitinib: an adverse effects profile. Expert Opin. Drug Saf. 5 (2006) 469-479
7. Chan H.W., Jenkins A., Pipolo L., Hannan R.D., Thomas W.G., and Smith N.J. Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte hypertrophy. J. Recept. Signal Transduct. Res. 26 (2006) 659-677
8. Chan H.W., Smith N.J., Hannan R.D., and Thomas W.G. Tackling the EGFR in pathological tissue remodelling. Pulm. Pharmacol. Ther. 19 (2006) 74-78
9. Chen B., Bronson R.T., Klaman L.D., Hampton T.G., Wang J.F., Green P.J., Magnuson T., Douglas P.S., Morgan J.P., and Neel B.G. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat. Genet. 24 (2000) 296-299
10. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230 (1985) 1132-1139
11. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G., Ross Jr. J., Chien K.R., and Lee K.F. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8 (2002) 459-465
12. Dietrich W.F., Lander E.S., Smith J.S., Moser A.R., Gould K.A., Luongo C., Borenstein N., and Dove W. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75 (1993) 631-639
13. Disis M.L., and Rivkin S. Future directions in the management of ovarian cancer. Hematol. Oncol. Clin. North Am. 17 (2003) 1075-1085
14. Drolet M.C., Roussel E., Deshaies Y., Couet J., and Arsenault M. A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J. Am. Coll. Cardiol. 47 (2006) 850-855
15. Ellis A.G., Doherty M.M., Walker F., Weinstock J., Nerrie M., Vitali A., Murphy R., Johns T.G., Scott A.M., Levitzki A., McLachlan G., Webster L.K., Burgess A.W., and Nice E.C. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. Biochem. Pharmacol. 71 (2006) 1422-1434
16. Erickson S.L., O'Shea K.S., Ghaboosi N., Loverro L., Frantz G., Bauer M., Lu L.H., and Moore M.W. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2- and heregulin-deficient mice. Development 124 (1997) 4999-5011
17. Erlichman C., Hidalgo M., Boni J.P., Martins P., Quinn S.E., Zacharchuk C., Amorusi P., Adjei A.A., and Rowinsky E.K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 24 (2006) 2252-2260
18. Ewer M.S., Gibbs H.R., Swafford J., and Benjamin R.S. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?. Semin. Oncol. 26 (1999) 96-101
19. Fuchs I.B., Landt S., Bueler H., Kuehl U., Coupland S., Kleine-Tebbe A., Lichtenegger W., and Schaller G. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res. Treat. 82 (2003) 23-28
20. Fukazawa R., Miller T.A., Kuramochi Y., Frantz S., Kim Y.D., Marchionni M.A., Kelly R.A., and Sawyer D.B. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J. Mol. Cell. Cardiol. 35 (2003) 1473-1479
21. Garcia-Rivello H., Taranda J., Said M., Cabeza-Meckert P., Vila-Petroff M., Scaglione J., Ghio S., Chen J., Lai C., Laguens R.P., Lloyd K.C., and Hertig C.M. Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H1153-H1160
22. Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., and Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378 (1995) 390-394
23. Gill G.N., Kawamoto T., Cochet C., Le A., Sato J.D., Masui H., McLeod C., and Mendelsohn J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259 (1984) 7755-7760
24. Goishi K., Lee P., Davidson A.J., Nishi E., Zon L.I., and Klagsbrun M. Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects. Mech. Dev. 120 (2003) 811-822
25. Grazette L.P., Boecker W., Matsui T., Semigran M., Force T.L., Hajjar R.J., and Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44 (2004) 2231-2238
26. Howes A.L., Miyamoto S., Adams J.W., Woodcock E.A., and Brown J.H. Galphaq expression activates EGFR and induces Akt mediated cardiomyocyte survival: dissociation from Galphaq mediated hypertrophy. J. Mol. Cell. Cardiol. 40 (2006) 597-604
27. Iwamoto R., Yamazaki S., Asakura M., Takashima S., Hasuwa H., Miyado K., Adachi S., Kitakaze M., Hashimoto K., Raab G., Nanba D., Higashiyama S., Hori M., Klagsbrun M., and Mekada E. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3221-3226
28. Jackson L.F., Qiu T.H., Sunnarborg S.W., Chang A., Zhang C., Patterson C., and Lee D.C. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J. 22 (2003) 2704-2716
29. Jimeno A., and Hidalgo M. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim. Biophys. Acta 1766 (2006) 217-229
30. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., and Haber D.A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7665-7670
31. Lazar L.M., and Blum M. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease protection assay. J. Neurosci. 12 (1992) 1688-1697
32. Lee K.F., Simon H., Chen H., Bates B., Hung M.C., and Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378 (1995) 394-398
33. Lenferink A.E., Simpson J.F., Shawver L.K., Coffey R.J., Forbes J.T., and Arteaga C.L. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+MMTV/TGF-alpha bigenic mice. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9609-9614
34. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
35. Liu X., Gu X., Li Z., Li X., Li H., Chang J., Chen P., Jin J., Xi B., Chen D., Lai D., Graham R.M., and Zhou M. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol. 48 (2006) 1438-1447
36. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
37. Markman M. Viewing ovarian cancer as a "chronic disease": what exactly does this mean?. Gynecol. Oncol. 100 (2006) 229-230
38. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107 (2006) 1207-1218
39. Masui H., Kawamoto T., Sato J.D., Wolf B., Sato G., and Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44 (1984) 1002-1007
40. Michener C.M., and Belinson J.L. Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease. Oncology (Williston Park) 19 (2005) 1277-1285 Discussion 1285, 1288, 1293
41. Negro A., Brar B.K., and Lee K.F. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog. Horm. Res. 59 (2004) 1-12
42. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 37 Suppl 4 (2001) S9-S15
43. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., Chien K.R., Birchmeier C., and Garratt A.N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8880-8885
44. Pareja M., Sanchez O., Lorita J., Soley M., and Ramirez I. Activated epidermal growth factor receptor (ErbB1) protects the heart against stress-induced injury in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285 (2003) R455-R462
45. Partik G., Hochegger K., Schorkhuber M., and Marian B. Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J. Cancer Res. Clin. Oncol. 125 (1999) 379-388
46. Rabinowits G., Herchenhorn D., Rabinowits M., Weatge D., and Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 14 (2003) 665-668
47. Roberts R.B., Arteaga C.L., and Threadgill D.W. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell 5 (2004) 115-120
48. Roberts R.B., Min L., Washington M.K., Olsen S.J., Settle S.H., Coffey R.J., and Threadgill D.W. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1521-1526
49. Rohrbach S., Niemann B., Silber R.E., and Holtz J. Neuregulin receptors erbB2 and erbB4 in failing human myocardium-depressed expression and attenuated activation. Basic Res. Cardiol. 100 (2005) 240-249
50. Rohrbach S., Yan X., Weinberg E.O., Hasan F., Bartunek J., Marchionni M.A., and Lorell B.H. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 100 (1999) 407-412
51. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol. 19 (1995) 183-232
52. Sato J.D., Kawamoto T., Le A.D., Mendelsohn J., Polikoff J., and Sato G.H. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1 (1983) 511-529
53. Schaller G., Bangemann N., Becker C., Buhler H., Opri F., and Weitzel H.K. Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein. J. Cancer Res. Clin. Oncol. 125 (1999) 520-524
54. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 (2000) 211-225
55. Schneider J.W., Chang A.Y., and Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin. Oncol. 29 (2002) 22-28
56. Schneider J.W., Chang A.Y., and Rocco T.P. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin. Oncol. 28 (2001) 18-26
57. Snyderman, N., 2007. Cancer is no longer a death sentence. Elizabeth Edwards joins millions living with cancer as a chronic illness. In NBC Nightly News (id 17760785).
58. Srinivasan R., Poulsom R., Hurst H.C., and Gullick W.J. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 185 (1998) 236-245
59. Steeghs N., Nortier J.W., and Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 14 (2007) 942-953
60. Stern L.E., Falcone Jr. R.A., Kemp C.J., Braun M.C., Erwin C.R., and Warner B.W. Salivary epidermal growth factor and intestinal adaptation in male and female mice. Am. J. Physiol. Gastrointest. Liver Physiol. 278 (2000) G871-G877
61. Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., and Discafani C.M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6 (2000) 1024-1028
62. Uray I.P., Connelly J.H., Thomazy V., Shipley G.L., Vaughn W.K., Frazier O.H., Taegtmeyer H., and Davies P.J. Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. J. Heart Lung Transplant 21 (2002) 771-782
63. Wells A. EGF receptor. Int. J. Biochem. Cell. Biol. 31 (1999) 637-643
64. Wissner A., Overbeek E., Reich M.F., Floyd M.B., Johnson B.D., Mamuya N., Rosfjord E.C., Discafani C., Davis R., Shi X., Rabindran S.K., Gruber B.C., Ye F., Hallett W.A., Nilakantan R., Shen R., Wang Y.F., Greenberger L.M., and Tsou H.R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 46 (2003) 49-63
65. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82 (1999) 241-250
66. Yamamoto N., Horiike A., Fujisaka Y., Murakami H., Shimoyama T., Yamada Y., and Tamura T. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother. Pharmacol 61 (2008) 489-496
67. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., and Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319 (1986) 230-234
68. Yoneda K.Y., Hardin K.A., Gandara D.R., and Shelton D.K. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin. Lung Cancer 8 Suppl 1 (2006) S31-S35
69. Zhai P., Galeotti J., Liu J., Holle E., Yu X., Wagner T., and Sadoshima J. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ. Res. 99 (2006) 528-536
70. Zhao Y.Y., Feron O., Dessy C., Han X., Marchionni M.A., and Kelly R.A. Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes. Circ. Res. 84 (1999) 1380-1387
71. Zhao Y.Y., Sawyer D.R., Baliga R.R., Opel D.J., Han X., Marchionni M.A., and Kelly R.A. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 273 (1998) 10261-10269
72. Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D., and Zeng Y.X. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 169 (2001) 27-32